Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Proliferative Diabetic Retinopathy

In brief

This is a phase I/II open label, randomized, interventional clinical trial. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) \<21 days but \>7 days prior to vitrectomy and one intraoperative IAI at end of surgery followed by randomization in a 1:1 ratio into either 4 mandatory postoperative q4weeks IAI followed by mandatory q8 weeks IAI for 52 weeks follow-up (q8 week Group) or 2 mandatory postoperative q4weeks IAI followed by mandatory q16 weeks IAI for 52 weeks follow-up (q16 week Group).

Key facts

Study ID

NCT02976012

Run by

Southeast Retina Center, Georgia

People needed

24

Starts

2016-06-01

Expected to finish

2018-06-01

Last updated by the study team

2016-11-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adults age >18 years with Diabetes Mellitus
• PDR- related vitreous hemorrhage and not of another cause
• BCVA Vision LP or better
• Investigator determination that vitrectomy indicated for PDR-related vitreous hemorrhage
• Willing and able to comply with clinic visits and study-related procedures
• Provide HIPPA and signed informed consent prior to any study procedures

You may not qualify if…

• A condition per investigator opinion, would preclude participation in the study (unstable medical status, cardiovascular disease, glycemic control, inability to follow up etc.)
• Participation in an investigational trial within 30 days of enrollment
• Known allergy to IAI
• Systemic anti-VEGF or pro-VEGF treatment within 4 months of enrollment
• For women of childbearing age, pregnant or lactating or intending to become pregnant within the next 3 years
• History of PRP or peripheral retinal cryopexy or peripheral retinopexy for any reason in the study eye
• History of vitrectomy in the study eye
• History or evidence for rhegmatogenous retinal detachment in the study eye
• Evidence of traction retinal detachment involving or threatening central macula in the study eye
• Exam evident of external ocular infection (i.e. conjunctivitis, significant blepharitis, chalazion etc)
• Intravitreal anti-VEGF injection in the study eye <4weeks from enrollment.
• Pregnant or breast-feeding women
• Sexually active men* or women of childbearing potential** who are unwilling to practice adequate contraception during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm plus contraceptive sponge, foam, or jelly) *Contraception is not required for men with documented vasectomy. **Postmenopausal women must be amenorrheic for at least 12 months in order not to be considered of child bearing potential. Pregnancy testing and contraception are not required for women with documented hysterectomy or tubal ligation.

Where it is running

• Southeast Retina Center, PC — Augusta, Georgia, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.